Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FATE Fate Therapeutics

Trading 07-01 14:54:58 EDT

2.97

+0.27

+10.00%

High3.09	Low2.64	Vol4.39M
Open2.65	D1 Closing2.70	Amplitude16.67%
Mkt Cap345.30M	Tradable Cap299.37M	Total Shares116.26M
T/O13.07M	T/O Rate4.36%	Tradable Shares100.80M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"FATE","market":"US","secType":"STK","nameCN":"Fate Therapeutics","latestPrice":2.97,"timestamp":1782932091058,"preClose":2.7,"halted":0,"volume":4391286,"delay":0,"changeRate":0.1,"floatShares":100797117,"shares":116263459,"eps":-1.089789,"marketStatus":"Trading","change":0.27,"latestTime":"07-01 14:54:58 EDT","open":2.65,"high":3.09,"low":2.64,"amount":13068910.655886,"amplitude":0.166667,"askPrice":2.98,"askSize":700,"bidPrice":2.97,"bidSize":900,"shortable":3,"etf":0,"ttmEps":-1.089789,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1782936000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1380600000000,"exchange":"NASDAQ","adjPreClose":2.7,"preHourTrading":{"tag":"盘前","latestPrice":2.68,"preClose":2.7,"latestTime":"09:25 EDT","volume":7077,"amount":18980.641386,"timestamp":1782912301903,"change":-0.02,"changeRate":-0.007407,"amplitude":0.058704},"postHourTrading":{"tag":"盘后","latestPrice":2.68,"preClose":2.7,"latestTime":"19:57 EDT","volume":10791,"amount":29045.4264,"timestamp":1782863848074,"change":-0.02,"changeRate":-0.007407,"amplitude":0.022148},"volumeRatio":0.658747,"impliedVol":1.5346,"impliedVolPercentile":0.741},"requestUrl":"/m/hq/s/FATE","defaultTab":"news","newsList":[{"id":"2645890886","title":"H.C. Wainwright Reaffirms Their Buy Rating on Fate Therapeutics (FATE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645890886","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645890886?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:35","pubTimestamp":1782300949,"startTime":"0","endTime":"0","summary":"In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Fate Therapeutics, with a price target of $7.00. According...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-fate-therapeutics-fate-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-fate-therapeutics-fate-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645107522","title":"Fate Therapeutics (FATE) Gets a Buy from Mizuho Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2645107522","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645107522?lang=en_us&edition=fundamental","pubTime":"2026-06-22 23:15","pubTimestamp":1782141313,"startTime":"0","endTime":"0","summary":"In a report released today, from Mizuho Securities maintained a Buy rating on Fate Therapeutics, with a price target of $8.00. Currently, the analy...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/fate-therapeutics-fate-gets-a-buy-from-mizuho-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/fate-therapeutics-fate-gets-a-buy-from-mizuho-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","BK4139","FATE","MFG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643789310","title":"Fate Therapeutics Shareholders Back Directors and Governance Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2643789310","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643789310?lang=en_us&edition=fundamental","pubTime":"2026-06-16 05:12","pubTimestamp":1781557956,"startTime":"0","endTime":"0","summary":"An announcement from Fate Therapeutics ( ($FATE) ) is now available. At its annual meeting of stockholders held on June 12, 2026, Fate Therapeutics...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fate-therapeutics-shareholders-back-directors-and-governance-plans?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fate-therapeutics-shareholders-back-directors-and-governance-plans?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643078538","title":"Fate Therapeutics shareholders approve 7 million-share increase to equity incentive plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2643078538","media":"Reuters","labels":["executive","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643078538?lang=en_us&edition=fundamental","pubTime":"2026-06-16 04:04","pubTimestamp":1781553848,"startTime":"0","endTime":"0","summary":"Fate Therapeutics held its annual shareholder meeting on June 12, 2026.Shareholders adopted a third amended and restated 2022 Stock Option and Incentive Plan, adding 7 million shares to the pool.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 15, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL5pvfBm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643209973","title":"BRIEF-Fate Therapeutics Appoints Laura Hamill To Board Of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2643209973","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643209973?lang=en_us&edition=fundamental","pubTime":"2026-06-15 21:47","pubTimestamp":1781531235,"startTime":"0","endTime":"0","summary":"BRIEF-Fate Therapeutics Appoints Laura Hamill To Board Of DirectorsJune 15 (Reuters) - Fate Therapeutics Inc FATE.O:FATE THERAPEUTICS APPOINTS LAURA HAMILL TO BOARD OF DIRECTORSSource text: ID:nGNXbBYhvsFurther company coverage: FATE.O ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nTUA1G2JY7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643205812","title":"Fate Therapeutics appoints former Gilead commercial chief Laura Hamill to board","url":"https://stock-news.laohu8.com/highlight/detail?id=2643205812","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643205812?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:30","pubTimestamp":1781526642,"startTime":"0","endTime":"0","summary":"Fate Therapeutics appointed Laura Hamill to its board on June 15, 2026.Hamill previously served as EVP, Worldwide Commercial Operations at Gilead Sciences, overseeing about $22 billion in annual revenue.She spent nearly two decades at Amgen, including as SVP, U.S. Commercial Operations, leading a business unit representing roughly 80% of company revenue.Fate is positioning for later-stage development and an expected transition toward commercialization of its iPSC-derived cell therapy programs.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDL5dVbRv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU0965509010.AUD","FATE","LU0122379950.USD","LU1934455194.USD","IE00BJT1NW94.SGD","IE00BKVL7J92.USD","SG9999015945.SGD","LU0234570918.USD","LU1061106388.HKD","LU0868494617.USD","SG9999015952.SGD","SG9999014005.SGD","LU0058720904.USD","LU1023059063.AUD","LU0314104364.USD","IE00B3QW5Z07.USD","LU1037948541.HKD","LU1066053197.SGD","LU0861579265.USD","LU2242652126.USD","LU2242646821.SGD","IE00B4R5TH58.HKD","LU2210150020.SGD","LU1839511570.USD","AMGN","LU0965509101.SGD","LU2468319806.SGD","LU0823416689.USD","GILD","LU2095319765.USD","IE00BGHQF748.EUR","LU2112291526.USD","SG9999014039.USD","IE00BN0W2T93.GBP","BK4568","BK4533","LU0109394709.USD","SG9999014021.USD","BK4599","BK4581","BK4139","LU0320765992.SGD","LU2324357040.USD","IE00B7SZLL34.SGD","BK4578","LU0965509283.SGD","BK4534","NDAQ","IE00BSNM7G36.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643203047","title":"Press Release: Fate Therapeutics Appoints Laura Hamill to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2643203047","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643203047?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:30","pubTimestamp":1781526600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, June 15, 2026  -- Fate Therapeutics, Inc. , a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell -derived cellular immunotherapies broadly to patients with cancer and autoimmune diseases, today announced the appointment of Laura Hamill to its Board of Directors. Ms. Hamill is a global senior executive with more than three decades of commercial and strategic management experience across the biopharmaceutical industry.Ms. Hamill most recently served as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc., where she was responsible for approximately $22 billion in annual revenue and an organization of 2,500 employees. In that role she led the transformation of Gilead's global commercial organization, advancing its structure, governance and capabilities, to return the business to revenue growth. Prior to Gilead, Ms. Hamill spent nearly two decades at Amgen, where she was repeated","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642628154","title":"Piper Sandler Remains a Buy on Fate Therapeutics (FATE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2642628154","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642628154?lang=en_us&edition=fundamental","pubTime":"2026-06-09 19:18","pubTimestamp":1781003890,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Fate Therapeutics today and set a price target of $6.00. Tenthoff covers the Healt...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-remains-a-buy-on-fate-therapeutics-fate-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-remains-a-buy-on-fate-therapeutics-fate-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641485788","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2641485788","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641485788?lang=en_us&edition=fundamental","pubTime":"2026-06-08 18:30","pubTimestamp":1780914611,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Fate Therapeutics (FATE), Atai Beckley N.V. (ATAI) a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-210?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-210?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ATAI","BK4007","BK4539","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641548598","title":"Fate Therapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2641548598","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641548598?lang=en_us&edition=fundamental","pubTime":"2026-06-08 18:30","pubTimestamp":1780914600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FATE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 08, 2026 06:30 ET (10:30 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641144532","title":"Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Fate Therapeutics (FATE) and Edgewise Therapeutics (EWTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2641144532","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641144532?lang=en_us&edition=fundamental","pubTime":"2026-06-06 01:21","pubTimestamp":1780680104,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on United Therapeutics (UTHR), Fate Therapeutics (FATE) and Edgewise...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-united-therapeutics-uthr-fate-therapeutics-fate-and-edgewise-therapeutics-ewtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-united-therapeutics-uthr-fate-therapeutics-fate-and-edgewise-therapeutics-ewtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UTHR","XBI","LU1571399168.USD","BK4532","HCSG","LU0128526141.USD","BK4007","BK4139","BK4585","BK4137","FATE","BK4588","LU0029874061.USD","BK4539","LU1699723380.USD","XLV","LABU","EWTX","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641316078","title":"Fate Therapeutics Advances Off-the-Shelf CAR-T Autoimmune Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2641316078","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641316078?lang=en_us&edition=fundamental","pubTime":"2026-06-05 06:18","pubTimestamp":1780611497,"startTime":"0","endTime":"0","summary":"Fate Therapeutics ( ($FATE) ) has shared an announcement. On June 4, 2026, Fate Therapeutics updated its corporate presentation ahead of investor a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fate-therapeutics-advances-off-the-shelf-car-t-autoimmune-pipeline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fate-therapeutics-advances-off-the-shelf-car-t-autoimmune-pipeline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4022","CAR","BK4230","BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641161797","title":"Gil Blum Reiterates Hold on Fate Therapeutics as Early FT819 Data Show Promise but Uncertain Durability","url":"https://stock-news.laohu8.com/highlight/detail?id=2641161797","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641161797?lang=en_us&edition=fundamental","pubTime":"2026-06-05 02:25","pubTimestamp":1780597529,"startTime":"0","endTime":"0","summary":"Needham analyst Gil Blum has maintained their neutral stance on FATE stock, giving a Hold rating on May 21. Gil Blum has given his Hold rating due ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/gil-blum-reiterates-hold-on-fate-therapeutics-as-early-ft819-data-show-promise-but-uncertain-durability-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/gil-blum-reiterates-hold-on-fate-therapeutics-as-early-ft819-data-show-promise-but-uncertain-durability-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FATE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640815729","title":"Fate Therapeutics reports Phase 1 data for FT819 CAR-T in lupus with reduced conditioning regimen","url":"https://stock-news.laohu8.com/highlight/detail?id=2640815729","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640815729?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:33","pubTimestamp":1780576418,"startTime":"0","endTime":"0","summary":"Fate Therapeutics presented Phase 1 data at EULAR on FT819, an off-the-shelf anti-CD19 CAR T-cell therapy for systemic lupus erythematosus.Results showed rapid, sustained clinical improvement with a favorable tolerability profile under reduced-intensity conditioning, supporting outpatient, same-day discharge use.Findings also indicated durable B-cell depletion with a reset toward a healthier B-cell repertoire while preserving existing vaccine-derived immunity.The readout supported bendamustine as the preferred conditioning approach for RECLAIM-LN, a planned Phase 2 potentially registrational trial in lupus nephritis.Separate preclinical data presented for FT839 suggested broad elimination of disease-driving immune cells in rheumatoid arthritis samples without preconditioning, positioning a next-generation autoimmune program.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL7qVx4Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK4585","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014021.USD","IE00BN0W2W23.USD","LU0314104364.USD","SG9999014013.SGD","BK4139","NDAQ","BK4588","SG9999014005.SGD","BK4112","IE00BKPKM429.USD","IE00BN0W2V16.EUR","SG9999014039.USD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","FATE","LU2095319765.USD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640157248","title":"Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2640157248","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640157248?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:30","pubTimestamp":1780576200,"startTime":"0","endTime":"0","summary":"FT819 off-the-shelf CAR T-cell therapy product candidate continues to broaden patient access with 21 SLE patients now treated, including as outpatient administration in community hospitals Continued d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/04/3306754/24675/en/Fate-Therapeutics-Showcases-Data-from-FT819-and-FT839-Programs-at-the-European-Congress-of-Rheumatology-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065731478.USD","BK4077","BK4187","LU0963586101.USD","BK4022","CAR","FATE","IE0031619046.USD","CRS","IE00B7SZL793.SGD","IE00B19Z4B17.USD","SLE","IE00B66KJ199.SGD","BK4139","BK4006","BK4230","EPV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640184273","title":"Fate Therapeutics management to meet with Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2640184273","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640184273?lang=en_us&edition=fundamental","pubTime":"2026-06-04 04:55","pubTimestamp":1780520138,"startTime":"0","endTime":"0","summary":"Meeting to be held on June 8 hosted by Piper Sandler. Published first on TheFly – the ultimate source for real-time, market-moving breaking financi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-management-to-meet-with-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fate-therapeutics-management-to-meet-with-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640234059","title":"Fate Therapeutics grants 67,300 RSUs to two new hires under inducement plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2640234059","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640234059?lang=en_us&edition=fundamental","pubTime":"2026-06-03 04:05","pubTimestamp":1780430724,"startTime":"0","endTime":"0","summary":"Fate Therapeutics granted RSUs covering 67,300 common shares to two newly hired non-executive employees on June 1, 2026.Awards were issued under the Amended and Restated Inducement Equity Plan.RSUs vest over four years, with 25% vesting on each anniversary of the grant date, subject to continued employment.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDLbhyvV7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4588","BK4112","FATE","SG9999014021.USD","BK4585","LU2210150020.SGD","LU2095319765.USD","IE00BN0W2V16.EUR","BK4139","SG9999014039.USD","SG9999014005.SGD","LU0314104364.USD","IE00BN0W2W23.USD","SG9999014013.SGD","NDAQ","LU2210149790.SGD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640234659","title":"Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640234659","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640234659?lang=en_us&edition=fundamental","pubTime":"2026-06-03 04:05","pubTimestamp":1780430701,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUADR0BS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640492378","title":"Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640492378","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640492378?lang=en_us&edition=fundamental","pubTime":"2026-06-03 04:05","pubTimestamp":1780430700,"startTime":"0","endTime":"0","summary":"SAN DIEGO, June  02, 2026  (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3305584/24675/en/Fate-Therapeutics-Reports-New-Employee-Inducement-Awards-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640095144","title":"Fate Therapeutics reports early Phase 1 FT836 data showing tumor shrinkage in KRAS wild-type metastatic colorectal cancer without conditioning chemo","url":"https://stock-news.laohu8.com/highlight/detail?id=2640095144","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640095144?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:33","pubTimestamp":1780317218,"startTime":"0","endTime":"0","summary":"Fate Therapeutics reports early Phase 1 FT836 data showing tumor shrinkage in KRAS wild-type metastatic colorectal cancer without conditioning chemo. Fate Therapeutics presented preliminary Phase 1 data for off-the-shelf CAR T-cell candidate FT836 at the 2026 ASCO annual meeting.Early results showed tumor shrinkage signals in heavily pre-treated KRAS wild-type metastatic colorectal cancer without conditioning chemotherapy.Safety profile appeared favorable, with no severe immune-related toxicities reported in the initial patient set.Drug cells were detected in blood and later in tumor tissue, supporting trafficking and functional persistence without lymphodepletion.Company signaled a strategic focus on KRAS wild-type colorectal cancer as enrollment continues.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDLb9BMwB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2210150020.SGD","LU2210149790.SGD","LU2095319765.USD","BK4112","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","SG9999014005.SGD","NDAQ","FATE","IE00BGHQF748.EUR","BK4139","LU0314104364.USD","SG9999014039.USD","SG9999014013.SGD","SG9999014021.USD","BK4588","IE00BKPKM429.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.fatetherapeutics.com","stockEarnings":[{"period":"1week","weight":0.25},{"period":"1month","weight":-0.0493},{"period":"3month","weight":1.1774},{"period":"6month","weight":1.7478},{"period":"1year","weight":1.4107},{"period":"ytd","weight":1.7478}],"compareEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":-0.0128},{"period":"3month","weight":0.1397},{"period":"6month","weight":0.0951},{"period":"1year","weight":0.2087},{"period":"ytd","weight":0.0951}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.049458},{"month":2,"riseRate":0.615385,"avgChangeRate":0.078089},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.020579},{"month":4,"riseRate":0.615385,"avgChangeRate":0.004138},{"month":5,"riseRate":0.461538,"avgChangeRate":0.079338},{"month":6,"riseRate":0.461538,"avgChangeRate":-0.000833},{"month":7,"riseRate":0.416667,"avgChangeRate":0.050198},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.024603},{"month":9,"riseRate":0.416667,"avgChangeRate":0.00072},{"month":10,"riseRate":0.25,"avgChangeRate":-0.091603},{"month":11,"riseRate":0.538462,"avgChangeRate":0.090829},{"month":12,"riseRate":0.538462,"avgChangeRate":0.045045}],"exchange":"NASDAQ","name":"Fate Therapeutics","nameEN":"Fate Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Fate Therapeutics,FATE,Fate Therapeutics股票,Fate Therapeutics股票老虎,Fate Therapeutics股票老虎国际,Fate Therapeutics行情,Fate Therapeutics股票行情,Fate Therapeutics股价,Fate Therapeutics股市,Fate Therapeutics股票价格,Fate Therapeutics股票交易,Fate Therapeutics股票购买,Fate Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Fate Therapeutics(FATE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Fate Therapeutics(FATE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}